Hutchmed announced that Inmagene Biopharmaceuticals, a clinical stage biotechnology company developing differentiated therapies for immunological and inflammatory diseases, exercised the option to obtain an exclusive, worldwide and royalty-bearing license for IMG-007, a non-depleting humanized anti-OX40 mAb, and IMG-004, an oral non-covalent and reversible BTK inhibitor, with the right to sublicense through multiple tiers. The option was exercised pursuant to a collaboration between Inmagene and Hutchmed announced in 2021 to develop and commercialize a portfolio of drug candidates for I&I diseases. IMG-007 is being evaluated in Phase 2a studies in two indications: moderate-to-severe atopic dermatitis and alopecia areata. IMG-004 is being evaluated in a Phase 1 multiple ascending dose study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCM:
- HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
- HUTCHMED to Announce 2023 Final Results
- Hutchmed announces marketing approval of Elunate in Hong Kong
- HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
- HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
